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Pellular Immunostaining of Angiotensin-Converting
nzyme in Human Coronary Atherosclerotic Plaques
lavio Ribichini, MD,* Francesco Pugno, MD,† Valeria Ferrero, MD,* Gianni Bussolati, MD, FRCPATH,‡
auro Feola, MD,† Paolo Russo, MD,§ Carlo Di Mario, MD, Antonio Colombo, MD,
orrado Vassanelli, MD*
ovara, Cuneo, Torino, and Milano, Italy
OBJECTIVES The aim of this study was to determine the cellular localization of angiotensin I-converting
enzyme (ACE) in the atherosclerotic plaque and its correlation with inflammation and
cellular proliferation.
BACKGROUND Angiotensin I-converting enzyme inhibitors reduce the incidence of vascular events; therefore,
tissue ACE may play a determinant role in the pathophysiology of the atherosclerotic plaque.
METHODS Histology and immunocytochemistry of de novo coronary plaques retrieved with directional
coronary atherectomy from 141 patients were analyzed: 87 with stable angina, 39 with
subacute unstable angina, and 15 with acute unstable angina.
RESULTS Compared with stable patients, unstable patients showed more thrombotic lesions (72% vs.
27%, p  0.0001), smaller areas of fibrous plaque (2.3  1.2 mm2 vs. 2.8  1.1 mm2, p 
0.02), higher cellular proliferative score (0.78 0.9 vs. 0.27 0.6, p 0.003), larger content
of ACE-stained cells (26.3  23% vs. 12.6  15%, p  0.005) and larger areas of
inflammation as identified by CD68 immunostaining (29.5  22% vs. 20.2  19%, p 
0.02). A significant linear correlation was found between CD68- and ACE-stained areas
(mm2) among unstable patients (r 0.6, p 0.0001), but it was absent among stable patients
(r  0.006, p  0.9). Co-localization of ACE, CD68, and alpha-actin was confirmed by
double immunostaining. Patients with Ki-67–positive staining as an index of cell proliferation
showed also significantly larger areas of ACE immunoactivity (p  0.004).
CONCLUSIONS Our data demonstrate ACE immunoactivity in inflammatory and proliferative cells of
coronary atherosclerotic plaques. In particular, patients with unstable angina showed larger
areas of ACE immunoactive tissue and proliferating cells compared with stable patients.
These observations support a role of the enzyme in the pathophysiology of coronary unstable
plaques and suggest potentially different effects of ACE inhibitors according to clinical
presentation. (J Am Coll Cardiol 2006;47:1143–9) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.022Cardiology Foundation
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pngiotensin I-converting enzyme (ACE) inhibitors cause a
ignificant reduction in mortality, recurrence of acute myo-
ardial infarction (MI), new episodes of unstable angina,
nd need for new coronary revascularization procedures in
atients with left ventricular dysfunction (1). Many of these
nitial observations have been confirmed also in patients at
igh risk for vascular events and normally functioning hearts
reated with ramipril in the Heart Outcomes Prevention
valuation (HOPE) trial (2). In a lower-risk population
ith stable coronary heart disease, perindopril reduced the
ccurrence of death and MI, but did not prevent episodes of
nstable angina or the need for myocardial revasculariza-
ion in the European Trial on Reduction of Cardiac
vents With Perindopril on Stable Coronary Artery
isease (EUROPA) (3). In the most recent Prevention of
vents with Angiotensin Converting Enzyme Inhibition
PEACE) trial, trandolapril did not reduce clinical events in
atients with stable coronary heart disease and preserved left
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el Piemonte Orientale, Novara, Italy; †Ospedale Santa Croce e Carle, Cuneo, Italy;
Dipartimento di Scienze Biomediche dell’Universita’ di Torino, Torino, Italy;
Clinica Villa Maria Pia, Torino, Italy; and Centro Cuore Columbus, Ospedale San
affaele, Milano, Italy.i
Manuscript received May 31, 2005; revised manuscript received August 30, 2005,
ccepted September 8, 2005.entricular function (4). Explanations for the discrepancies
mong these trials remain merely speculative; they may
erive from the different use of concomitant treatments, or
ather be due to a lower basal extent of activation of the
enin-angiotensin system in stable patients with preserved
eft ventricular function (5).
In the normal heart, tissue ACE seems not to be required
or normal heart development, and angiotensin II is not
ecessary for normal cardiac function (6). Conversely, any
ind of injury to the heart results in marked ACE induction;
n particular inflammation causes accumulation of angioten-
in II as macrophages over-express ACE in interstitial sites
6,7). Angiotensin II contributes to the initiation and
rogression of atherosclerosis by increasing oxidative
tress, enhancing the adrenergic state, stimulating plas-
inogen activator inhibitor-1 production, and increasing
latelet aggregation (1,5–7). Conversely, the reduction of
ngiotensin II and the preservation of bradykinin and
itric oxide production that derives from the inhibition of
he ACE may account for the vascular protection pro-
ided by these drugs. Therefore, ACE activity in the
oronary atherosclerotic plaque is likely to be a patho-
hysiologic substratum for the clinical benefits of ACE
nhibition.
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ACE in Coronary Plaques March 21, 2006:1143–9Previous studies have described the cellular composition
f atherosclerotic plaques that cause stable or unstable
oronary syndromes (8). Diet et al. demonstrated the
resence of ACE in human atherosclerotic coronary arteries
y means of immunostaining (9), and increased tissue ACE
ctivity in plaques of patients with acute coronary syn-
romes (ACS) has been reported (10).
Plasma ACE level is under genetic control, and the
nsertion/deletion (ID) polymorphism of the ACE gene is a
arker of the ACE activity (11). The relationship between
D polymorphism, plasma ACE, and tissue ACE is not
ully defined.
We hypothesized that the ACE present in the plaque
ould be involved with mechanisms that rule the patient’s
linical outcome because of its existence in inflammatory
ells of vulnerable plaques that may cause clinical events.
herefore, we analyzed specially stained histology sections
f coronary atherectomy samples retrieved from patients
ith well characterized stable or unstable angina to deter-
ine if the intracellular enzyme was co-localized with
ellular markers of inflammation and cell proliferation.
urthermore, the ID polymorphism of the ACE gene and
he serum levels of the enzyme were also determined in
on–ACE-inhibited patients and correlated to tissue ACE
taining.
ETHODS
atient population. A total of 141 directional coronary
therectomy (DCA) specimens obtained from native coro-
ary arteries were analyzed. Each one corresponds to a
ingle “de novo” lesion per patient, responsible for the
linical presentation (culprit lesion). All patients had stable
ngina or silent ischemia, or unstable angina classified
ccording to Braunwald’s definition (12), and all gave
nformed consent to undergo DCA. The study protocol was
pproved by each of the relevant institutions where the
CA procedures were performed.
The DCA specimens were obtained after multiple cuts
nd immediately immersed in 4% buffered formalin. Sam-
les were processed for paraffin embedding according to
onventional techniques to perform hematoxylin-eosin and
mmunocytochemistry staining.
ematoxylin-eosin histology. The total and segmental
rea for each plaque sample and areas of each cellular
omponents were quantified by accurate computer-aided
Abbreviations and Acronyms
ACE  angiotensin I-converting enzyme
ACS  acute coronary syndromes
DCA  directional coronary atherectomy
HPF  high-power fields
ID  insertion/deletion
MI  myocardial infarction
SMC  smooth muscle cellslanimetry of each specimen using an acquisition program Amage Pro Plus (software version 4.0, Media Cybernetics,
ilver Spring, Maryland). The characteristics of each coro-
ary plaque were classified as being atheroma (necrotic cores
nd cholesterol clefts without connective tissue matrix) or
brocellular, graded as paucicellular or fibrotic (30 spin-
led cells in high-power fields [HPF]), moderately cellular
30 to 100 spindled cells in HPF), and hypercellular (100
pindled cells in HPF). Thrombi and calcium were also
nalyzed qualitatively and as a percent of the surface of the
laque area. Thus, plaque material from each patient could
ontain up to six different histologic characteristics. All
lassifications and measurements were performed blindly of
he clinical presentation.
ntibody staining. Immunostaining for the detection of
mooth muscle cells (SMC), macrophages, cells containing
CE and proliferation marker Ki-67 were performed in
amples from all patients. Respectively, sections were
tained with 0.66 g/ml anti-SMC (anti-human alpha-
mooth muscle actin clone 1A4 [M 851; DAKO, Milan,
taly]); 0.1 g/ml anti-CD68 (anti-human macrophage
able 1. Clinical Data in 141 Patients With Stable or
nstable Angina
Clinical Data
Stable
(n  87)
Unstable
(n  54) p Value
ge 59  10 58  7 0.2
emale gender 2 (2.3%) 6 (11.1%) 0.03
iabetes 13 (14.9%) 10 (18.5%) 0.6
ypertension 53 (60.9%) 31 (57.4%) 0.7
moking habit 24 (27.6%) 27 (50%) 0.007
amily history of CAD 37 (42.5%) 19 (35.2%) 0.4
ypercholesterolemia 63 (72.4%) 33 (61.1%) 0.2
essel treated
LAD 71 (81.6%) 44 (81.4%)
RCA 10 (11.5%) 5 (9.3%) 0.9
LCx 6 (6.9%) 5 (9.3%)
esion type
A — 2 (3.7%)
B1 19 (21.8%) 16 (29.6%)
B2 48 (55.2%) 27 (50%) 0.3
C 20 (23%) 9 (16.7%)
egree of CAD
1-vessel disease 36 (41.4%) 29 (53.7%)
2-vessel disease 36 (41.4%) 21 (38.9%) 0.2
3-vessel disease 15 (17.2%) 4 (7.4%)
AD  coronary artery disease; LAD  left anterior descendent; LCx  left
ircumflex; RCA  right coronary artery.
able 2. Medical Treatment at the Time of Directional
oronary Atherectomy
Medical Treatment
Stable
(n  87)
Unstable
(n  54) p Value
eta-blockers 39 (45%) 31 (57.4%) 0.3
alcium channel blockers 35 (40%) 20 (37%) 0.7
CE inhibitors 18 (20.7%) 20 (37%) 0.03
tatins 42 (48%) 20 (37%) 0.3
spirin 79 (91%) 49 (91%) 0.8
iclopidine or clopidogrel 82 (94.3%) 54 (100%) 0.9
lycoprotein IIb/IIIa inhibitors 4 (4.6%) 6 (11.1%) 0.1CE  angiotensin I-converting enzyme.
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March 21, 2006:1143–9 ACE in Coronary Plaquesntibody clone KP-1 [M814; DAKO]); 10 g/ml ACE
anti-human ACE [BMA]; Biomedical AG, Augst, Swit-
erland); and cell proliferation was determined with anti-
uman Ki-67 antibody diluted 1:400 (clone MIB-1; Immu-
otech, Marseille, France). Positive controls were tested
sing normal human tissues of smooth muscle (normal
olon) for alpha-actin, spleen for KP-1, lung for ACE, and
ymphoid tissue for Ki-67. The degree of cellular prolifer-
tion was assessed on the Ki-67–stained sections according
o the graded MIB score (0 to 3) proposed by Flugelman et
l. (13).
ouble immunostaining. To identify cell types corre-
ponding to ACE-positive elements, we proceeded with a
equence of immunocytochemical reactions performed in
he same section using non–cross-reacting antibodies from
ifferent species, as described elsewhere (5,9), to identify
ells containing ACE and CD68 and cells containing ACE
nd alpha-smooth muscle actin.
The ID polymorphism of the ACE gene was determined
y polymerase chain reaction using 500 ng of genomic
eoxyribonucleic acid extracted from white blood cells as
Table 3. Histology and Immunocytochemistry
Stable (n 
mm2
Histology
Atheroma 1.1  0.9
Paucicellular (fibrous) 2.8  1.1
Moderatelly cellular 1.1  0.8
Hypercellular 1.1  1.1
Thrombus 0.8  0.7
Calcium 0.3  0.3
Total plaque area 3.9  1.1
Immunocytochemistry
Alpha-actin (SMC) 2.2  1.2 5
CD68 0.8  0.8 2
ACE 0.5  0.6 1
Ki-67 (proliferation score) 0.27  0.
ACE  angiotensin I-converting enzyme; SMC  smooth
able 4. Histologic Morphology and Immunocytochemistry Acco
n Acute or Subacute Subgroups
Stable (n  87) U
mm2 %
istology
Atheroma 1.1  0.98 31  30
Paucicellular 2.8  1.1 73  26*
Moderatelly cellular 1.0  0.6 25  15
Hypercellular 1.1  1.4 24  22
Thrombus 0.8  0.7 20  18*
Calcification 0.3  0.3 8.1  7.8 0
Total plaque area 3.9  1.1 100
mmunocytochemistry
Alpha-actin (SMC) 2.2  1.2 52  24
CD68 0.8  0.8 20  19*
ACE 0.5  0.6 12.6  15*
Ki-67 (proliferation score) 0.3  0.6*Notes significantly different values.
Abbreviations as in Table 3.reviously detailed (11). Serum ACE levels were measured
sing fluoril-acrioil-phenilalanilglycilglycina substratum
SIGMA, St. Louis, Missouri), as detailed in the same
revious work.
tatistical analysis. Continuous data are expressed as
eans and standard deviations; discrete variables are given
s absolute values and percentages. Two-tailed Student t
est was used for comparison of parametric variables and the
hi-square or exact test for discrete variables. A linear
egression analysis was used to correlate areas stained for
CE and inflammation (ACE and CD68 staining in mm2).
probability value of less than or equal to 5% was
onsidered significant.
ESULTS
aseline clinical data of the 141 patients are reported in
ables 1 and 2. Patients with unstable angina were more
requently females, smokers, and were under ACE inhibitor
reatment at the time of DCA. In most cases (70%), ACE
nhibitors were started at hospital admission.
atients With Stable or Unstable Angina
Unstable (n  54)
mm2 % p Value
31 1.0  0.7 24  19 0.5
26 2.3  1.2 57  25 0.02
21 1.2  0.9 28  20 0.6
18 1.8  0.9 40  20 0.03
18 1.2  0.8 30  23 0.02
8 0.3  0.4 8  9 0.9
3.9  0.9 100 0.9
24 2.2  0.9 56.3  23 0.6
19 1.2  1.0 29.5  22 0.02
15 1.2  1.1 26.3  23 0.005
0.78  0.9 0.003
e cells.
to Clinical Presentation; Unstable Angina Is Analyzed
le Subacute (n  39) Unstable Acute (n  15)
2 % mm2 % p Value
0.8 26  22 0.84  0.5 19  10 NS
1.2 57  23* 2.1  1.4 55  27* 0.05*
0.9 28  20 1.4  1.3 40  37 NS
0.9 39  20 1.1  0.3 32  10 NS
0.5 28  20 1.5  1.1 37  28* 0.05*
0.4 8.0  10 0.3  0.2 7  5 NS
0.9 100 3.8  1.1 100 NS
0.9 59  24 1.8  0.9 47  18 NS
1.0 29  23* 1.3  0.9 33  22 0.05*
1.0 25.5  21* 1.3  1.4 28.4  30* 0.05*
0.9  0.9* 0.6  0.9 0.05*in P
87)
%
31 
73 
28 
27 
20 
8 
100
4.1 
0.2 
2.6 
6rding
nstab
mm
1.1 
2.4 
1.2 
1.8 
1.1 
.31 
4.1 
2.3 
1.2 
1.1 
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ACE in Coronary Plaques March 21, 2006:1143–9lasma ACE levels and tissue ACE staining. At the time
f DCA, 38 patients were under ACE inhibitor treatment.
lasma ACE level was available in 95 of the 103 non–ACE-
nhibited patients, and the ID ACE genotype in 85. As
xpected, plasma ACE levels were higher in deletion/
eletion (DD) patients (41.8  17 U/l, n  17), interme-
iate in ID patients (22  10 U/l, n  52), and lower in
nsertion/insertion (II) patients (11.3 3 U/l, n  16), p
.001. In this population of non–ACE-inhibited patients,
lasma ACE concentrations (U/l) did not correlate with the
urface of ACE-stained cells (mm2): r  0.02, p  0.5,
hereas there was a significant correlation in the subgroup
f non–ACE-inhibited patients with unstable angina: r 
.65, p  0.02. Tissue ACE staining was different accord-
ng to the ID polymorphism: DD patients showed larger
reas of ACE-stained cells (14  21%) compared with ID
10.6  13%) and II (5  9%), respectively, p  0.05 for
D versus ID, and DD versus II. Such difference was more
ronounced in patients with unstable angina (DD: 28 
5%, ID: 12 8%, II: 2 7%, p 0.05 for DD vs. ID, and
D vs. II).
istology. The comparison of the histologic features ob-
erved between patients divided as having stable (n 87) or
nstable angina (n 54) shows that in unstable patients the
resence of thrombus was more frequent (39 patients 
2% vs. 23 patients  26%, p  0.0001), and plaque type
as predominantly hypercellular. The presence of calcium
n the plaques (25  29% vs. 12  22%, p  0.3) or
theromatous gruel (17  20% vs. 14  26%, p  0.5) was
imilar in the two groups. Detailed morphometric data
xpressed in mm2 and percent of the plaque surface are
isclosed in Table 3.
For further analysis of the histologic findings, patients
ith unstable angina were classified as having acute unstable
ngina (chest pain at rest in the last 48 h: 15 patients) or
ubacute unstable angina (asymptomatic for at least 48 h
efore DCA: 39 patients) (Table 4). Acute unstable patients
howed significantly less fibrotic tissue and some larger
mounts of thrombus (Table 4). In predominantly fibrous
laques, some lymphocytes and very few plasma cells, other
han SMC and macrophages, were observed in the fibrous
atrix. In moderately or highly cellular plaques, inflamma-
ory and spindled-shaped cells were the predominant types.
n plaques containing atheroma, rare giant cells were
resent next to the cholesterol clefts. Endothelial cells were
resent in neovessels of all types of plaque and in fragments
f intact intima.
mmunocytochemistry. The immunocytochemistry study
evealed that unstable patients had a significantly higher
roliferative score, larger content of ACE-stained cells, and
arger areas of inflammation characterized by CD68 immu-
ostaining (Table 3). In patients with acute unstable angina,
reas occupied by cells staining for ACE were larger and
reas of inflammation marker CD-68 tended to be also
arger compared with subacute unstable patients (Table 4). pThe vast majority of ACE-positive cells were observed in
reas of clustered cells also positive for inflammation CD68
mmunostaining in most cases. This finding was confirmed
y co-localization of ACE and CD68 antigen in fragments
nalyzed by means of double immunostaining (Fig. 1). By
inear regression analysis, a significant association was found
etween the area (mm2) occupied by macrophages (identi-
ed by CD68 immunostaining) and ACE-reactive areas in
atients with unstable angina: r 0.6, p 0.0001. In tissue
f patients with stable angina, such correlation was absent:
 0.006, p  0.9 (Fig. 2).
The content of ACE-stained cells observed in patients
howing areas of proliferating cells (Ki-67–positive staining
nd MIB score 1) was significantly larger than that of
igure 1. Double immunostaining of coronary plaque tissue from a
5-year-old man with subacute unstable angina. (A) Immunohistochemical
taining (red reaction product) using anti–angiotensin I-converting enzyme
ntibodies and an immuno-alkaline phosphatase reaction that identifies as
ngiotension I-converting enzyme-positive cells the endothelium and
umerous stromal cells, arranged in clusters or isolated in the stroma. (B)
fter removal of the red reaction product, the same area is stained in brown
ith an immunoperoxidase reaction revealing CD68-positive macro-
hages. Comparison of the two figures reveals also that some strongly
ngiotensin I-converting enzyme-positive cells do not correspond to
acrophages.atients without signs of cell proliferation, i.e. MIB score
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March 21, 2006:1143–9 ACE in Coronary Plaques(30.3  20% vs. 14.5  19%, p  0.004). Immunostain-
ng and cell quantification demonstrated that 90% of the
i-67–positive proliferating cells co-localized with CD68
ntigen-stained cells in identical sections, indicating their
nflammatory nature. The remaining 10% showed a spin-
led shape and co-localized with alpha-actin–stained cells,
ndicating the smooth muscle nature.
In areas of ACE-positive staining not associated to
nflammatory immunoreactivity, two different cell types
ere identified: endothelial cells of neovessels (Fig. 3) and
pindled-shaped cells of the neointima. Double immuno-
taining of such spindled cells with anti-ACE and anti-
lpha-actin antibodies demonstrated that approximately
5% of alpha-actin–positive spindled cells were also ACE-
igure 2. Linear regression of the association of macrophage area (mm2)
dentified by CD68 immunostaining and area of angiotensin
-converting enzyme-stained cells (mm2) in patients with stable angina
A) or unstable angina (B), showing both positive reactions. (A) r 
.006, p  0.9; (B) r  0.6, p  0.0001.ositive in the same sections, suggesting their SMC nature
s
nFig. 4). The quantitative distribution of these cells was not
ifferent among the three clinical groups.
ISCUSSION
ellular ACE in atherosclerotic plaques correlates with
nflammatory cells, cellular proliferation, and unstable clin-
cal presentation. Furthermore, the ID polymorphism of the
CE gene correlates with the tissue ACE immunostaining
n unstable patients.
In our study, areas occupied by macrophages were signif-
cantly associated with ACE-stained areas in unstable pa-
ients but not in stable patients (Fig. 2). This observation is
onsistent with the augmented expression of the enzyme
econdary to macrophage activation expected in ACS
9,14,15). Furthermore, larger areas of ACE immunoactivity
ere found in sections showing Ki-67–positive staining, sug-
esting that cell proliferation in the plaque may be associated
ith the enhanced availability of angiotensin II that derives
rom local ACE activity, an interesting mechanism previously
eported in primates and in humans by others (16).
Macrophages are known to up-regulate ACE activity up to
00-fold in vitro during differentiation (15); furthermore, the
o-localization of ACE, angiotensin II, and the type 1 receptor
or angiotensin II with macrophages at the site of rupture of
oronary atherosclerotic plaques in patients with ACS rein-
orces the hypothesis of a role of ACE in plaque instability and
he occurrence of clinical events (17). The beneficial anti-
therosclerotic properties of ACE inhibitors, found to be
ndependent of the blood pressure reduction, may be at least in
art due to the attenuation of the local effects induced by ACE
nd their destabilizing actions at the tissue plaque level (1,2).
Other ACE immunoreactive cells not related to macro-
hages were endothelial cells of neovessels (Fig. 3) and
pindled-shaped cells that showed alpha-actin immunoac-
ivity at double staining (Fig. 4), suggesting a role of the
nzyme in the neovascularization of the atherosclerotic
igure 3. Immunoreaction with angiotensin I-converting enzyme antibody
howing positive staining of the endothelial cells of neovessels of the
eointima (arrows).
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ACE in Coronary Plaques March 21, 2006:1143–9laque, and possibly in the transformation of SMC-like
ells from a dedifferentiated to a differentiated phenotypic
tate or from other types of cells such as infiltrating
acrophages or fibroblasts, as has been previously proposed
y other authors who analyzed sections of vessel wall from
utopsy specimens (14,15).
ACE inhibitors reduce plasma ACE levels independently
f the patient’s ID genotype (18), and preliminary observa-
ions suggest that they may also attenuate plaque tissue
CE immunostaining (5,19). However, the effectiveness of
CE inhibitors in the atherosclerotic plaque given at
onventional doses is unknown. Robust clinical data support
he efficacy of these drugs in reducing the incidence of major
linical events (death and MI), and minor events (angina
nd need for revascularization) in patients with severe
igure 4. Double immunostaining of coronary plaque tissue from a
1-year-old woman with subacute unstable angina stained in sequence as in
igure 1. Immunohistochemical procedure for angiotensin I-converting
nzyme (A: red color) and alpha-actin (B: brown color). Comparison of
he two figures demonstrates that some actin-positive cells of the smooth
uscle cell type are also angiotensin I-converting enzyme-positive.orbidity such as in survivors of a MI, patients with heartailure (1), or patients at high risk for vascular events (2,5).
ore recent investigations indicate that ACE inhibitors
ay exert fewer clinical benefits in less critical patients as
hose with stable coronary heart disease and preserved left
entricular function under conventional treatment (4). A
peculative interpretation for such observation could be that
f a different cellular substrate at the plaque level for ACE
nhibitors according to the clinical presentation of the
atient, with significantly less ACE immunoactivity in
table patients, as is suggested by our findings. The benefits
f ACE inhibitors may therefore be more consistent in the
ontext of an overexpression of the renin-angiotensin sys-
em as, for example, in patients with a recent MI, heart
ailure, or ACS.
tudy limitations. Directional coronary atherectomy
auses compression of some of the tissue as material is cut
nd extracted from the lumen side of the lesions, which
ormally accounts for one-third of the total plaque, and this
ay not reflect total plaque composition. Furthermore, the
ole of cells mainly present in the media or the adventitia
annot be assessed.
onclusions. The cellular localization of ACE in areas of
nflammation occupied by macrophages as well as in areas
ith proliferating cells supports a causative role of the
nzyme in the pathophysiology of ACS. The differences
egarding tissue ACE immunoactivity in stable and unstable
atients may account for potentially different effects of
CE-inhibitor drugs according to clinical presentation.
eprint requests and correspondence: Dr. Flavio Ribichini,
irector Catheterization Laboratory, Università del Piemonte
rientale, Ospedale Maggiore della Carità, Corso Mazzini 18,
8100 Novara, Italy. E-mail: flavio.ribichini@med.unipmn.it.
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